Cytori: A Low Risk Stem Cell Play
The biotech company has had successful clinical trials yet is unloved by the market. Here's why investors should start a position now.
In CHF, heart muscle function and activity are gradually but materially degraded. Generally, there is a central area of dead heart muscle surrounded by weakened heart muscle that doesn't get enough oxygen to return to normal beating heart muscle. Alive, but not beating heart muscle is pretty much useless. In this case, the ideal solution is to deliver ADRCs to the weakened tissue in hope that the ADRCs could help restore normal blood flow and start the weakened muscle beating again. To accomplish this, a highly sophisticated catheter manufactured by a division of Johnson & Johnson (JNJ) was used. This catheter was threaded down the coronary artery to the area of weakened heart muscle. An extremely small needle is inserted through the artery into the weakened tissue and a dose of ADRCs are delivered. Typically, this is repeated 10 to 15 times in different areas.
The Precise study produced the following results in the chart below. MVO2 is a measurement of how much oxygen the heart is consuming, which is directly related to how well it is beating and how much blood is being pumped.
Change in MVO2: Baseline to 18 months
CHF normally results in a slow, steady decline in heart function over time. The Precise results demonstrated a statistically significant difference from the patients that did not receive ADRCs. This is no magic rebuilding of heart muscle from scratch, just a logical "healing" approach to restore available weakened heart muscle back to functional use. It looks like it works.
You have to admit that these results look intriguing, but if ADRCs were designed to heal wounds before bandages and antibiotics, why didn't they heal heart attacks on their own? Perhaps the answer is that ADRCs evolved for skin and muscle wounds and these cells had to be close at hand and ready to act in a timely fashion. Damaged heart tissue was internal and remote to these cells, plus you have the cavemen gene exclusion principle. If cavemen didn't get heart attacks until after their kids reached adulthood, there was no natural selection opportunity to eliminate adult onset diseases. Heart attacks, diabetes, or Alzheimer's didn't matter if you already passed your bad genes on to your kids. Our 487th great, great grandfather was lucky if he got to be that old.
The other alternative to this theory is why didn't wound-healing stem cells evolve to circulate with the blood system? That's a good question, but it may simply be that the volume of additional cells required to be pumped by the heart all the time was not worth the biological effort. Plus, if the wound resulted in severely damaged blood vessels, circulating ADRCs might not be able to get to the wound at all. Either way, like all politics, ADRCs are local.
Next, let's address competition, patents, and cash.
At the moment, there are three approaches to cardiac stem cell treatments. Cytoria has worldwide patents on a process and automated device that uses your own (autologous) ADRCs from adipose tissue and can complete the process in a couple of hours. Nobody else has anything like it. Another autologous approach is to take stem cells from your bone morrow, but the quantity of stem cells that can be obtained this way is much too small for a therapeutic effect. The cells have to be cultured and grown to a therapeutic dose, which can take three days to three weeks. You might well die waiting for a dose. Compared to Cytori's technique, this approach makes no sense. The other approach is to take someone else's (allogenic) bone marrow stem cells, culture them, freeze them, store them, and then eventually use them. The timing is quick, but the expense of culturing the cells, maintaining quality controls, and ensuring consistency between donor batches will make that process much more expensive than Cytori's.
Cytori has 30 issued patents, more than 100 pending worldwide, and last week got a "foundational" Japanese patent for the Celution system. At the end of 2010, Cytori had roughly $50 million in cash although it had about $20 million in debt at the end of the third quarter of 2010, almost all of which was owed to General Electric (GE). Cytori has a partnership with GE Healthcare to distribute Celution in certain European countries -- an intriguing partner to say the least.
Putting all this information together, Cytori looks like it has excellent potential, good patents, and enough cash to complete its clinical trials. Is there any reason that you need to start a position now? I think there might be and it has to do with the CHF data that came out of Europe. As small as the CHF trial was, it produced statistically significant improvement in overall heart function. CHF means that your heart does not get enough oxygen to beat strongly enough to get enough blood to your lungs and body; therefore your long-term prognosis is not good. The surgical options to CHF are coronary bypass surgery or a heart transplant. If you no longer qualify for either of these options, you are called a no-option CHF patient.
You really don't want to be classified as no-option, and interestingly enough, the European regulatory agencies seem to agree. Let's step back and look at what Cytori already has done in the EU. The Celution system is approved for soft tissue repair. Autologous ADRCs concentrated and reinjected in clinical trials worked on stabilizing transplanted fat tissue. A small trial using autologous ADRCs in CHF has also produced statistically significant improvement in heart function.
A few months ago, when I talked to Cytori management, they discussed a possible narrow EU approval for CHF using the existing results for compassionate use. All of a sudden, the most recent corporate presentation predicts 200,000 new patients in the EU market every year for treating no-option CHF. At $5,000 to $10,000 per patient, that is a $1 billion to $2 billion market. Trying to game regulatory approvals isn't easy, if not dangerous, but my guess is that a 2011 approval isn't crazy. Again, your cells, no toxicity, looks like it works, and you have no options. How many people would say, "Let me try it," even if there is no initial insurance reimbursement?
Despite all of the apparent successes in clinical trials, Cytori is unloved by the market. There is a large short position of 6 million shares. Excluding management and partner shares, this is about 25% of the float. Although some of these short shares may be hedged against outstanding warrants, there is still a significant downside bet against Cytori. There are a few small brokerage firms that follow Cytori, and one flat out hates the stock with a $2 target.
I have a hard time understanding this. Is it because Cytori sells a device system and sales have been slow to ramp up? That's possible, but the initial approvals have not yet included insurance reimbursement. That should start to change in Europe with the soft tissue applications. Maybe it's that biotech analysts view Cytori as a medical device company, and the medical device analysts don't understand stem cells, look at weak sales growth, and simply don't care.
Either way, Cytori doesn't look like the typical binary biotech bet. The soft tissue and skin wound-healing applications look to me like high probability winners. If the cardiac applications prove out, Cytori will be a monster winner. I'm in the "tails you break even, heads it's a home run" camp.
Of course, timing is everything. Cytori management has indicated that they will update the status of the European no-option application on the earnings conference call on March 10. Maybe that will be the catalyst to draw attention to the possibility of a major stem cell approval in 2011 that seems to be under the radar screen of Wall Street.
Dig into the information at the Cytori company website and keep it on your watch list. I think there is a lot of potential here.
The information on this website solely reflects the analysis of or o=
pinion about the performance of securities and financial markets by the wri=
ters whose articles appear on the site. The views expressed by the writers =
are not necessarily the views of Minyanville Media, Inc. or members of its =
management. Nothing contained on the website is intended to constitute a re=
commendation or advice addressed to an individual investor or category of i=
nvestors to purchase, sell or hold any security, or to take any action with=
respect to the prospective movement of the securities markets or to solici=
t the purchase or sale of any security. Any investment decisions must be ma=
de by the reader either individually or in consultation with his or her inv=
estment professional. Minyanville writers and staff may trade or hold posit=
ions in securities that are discussed in articles appearing on the website.=
Writers of articles are required to disclose whether they have a position =
in any stock or fund discussed in an article, but are not permitted to disc=
lose the size or direction of the position. Nothing on this website is inte=
nded to solicit business of any kind for a writer's business or fund. M=
inyanville management and staff as well as contributing writers will not re=
spond to emails or other communications requesting investment advice.
Copyright 2011 Minyanville Media, Inc. All Rights Reserved.